Hormone replacement therapy and adverse outcomes in women with atrial fibrillation: An analysis from the atrial fibrillation follow-up investigation of rhythm management trial

Stroke

Volumn 45, Issue 10, 2014, Pages 3076-3079

  Apostolakis, Stavros ^a   Sullivan, Renee M ^b   Olshansky, Brian ^c   Lip, Gregory Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF MISSOURI   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

atrial fibrillation; hormone replacement therapy

Indexed keywords

WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HAZARD RATIO; HEART FAILURE; HEART INFARCTION; HEART RHYTHM; HORMONE SUBSTITUTION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPENSITY SCORE; RISK FACTOR; STROKE PATIENT; VENOUS THROMBOEMBOLISM; ADVERSE EFFECTS; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMPLICATION; ESTROGEN THERAPY; PROPORTIONAL HAZARDS MODEL;

AGED; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS;

EID: 84922481284     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.006668     Document Type: Article

References (10)

1. Wagstaff AJ, Overvad TF, Lip GY, Lane DA. Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation A systematic review and meta-analysis [published online ahead of print April 9, 2014]. QJM. doi: 10. 1093/qjmed/hcu054. http://qjmed. oxford journals. org/content/early/2014/04/09/qjmed. hcu054. full.
2. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-1833.
3. Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012;125:669-676.
4. Stroke-in-AF-Working-Group. Independent predictors of stroke in patients with atrial fibrillation: A systematic review. Neurology. 2007;69:546-554.
5. Atrial Fibrillation Investigators. Echocardiographic predictors of stroke in patients with atrial fibrillation: A prospective study of 1066 patients from 3 clinical trials. Arch Intern Med. 1998;158:1316-1320.
6. Banerjee A, Taillandier S, Olesen JB, Lane DA, Lallemand B, Lip GY, et al. Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: The Loire Valley Atrial Fibrillation Project. Eur J Heart Fail. 2012;14:295-301.
7. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
8. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605-613.
9. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: Analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke. 1999;30:1223-1229.
10. Platt AB, Localio AR, Brensinger CM, Cruess DG, Christie JD, Gross R, et al. Risk factors for nonadherence to warfarin: results from the IN-RANGE study. Pharmacoepidemiol Drug Saf. 2008;17: 853-860.